Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (51)	6/28/2000 10:35:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 724

>> Something big must be afoot! << Chuckle. Yeah, those 300 shares sent chills up my spine. Wheeeeeeeeee! >> Can anyone clue me in on what "everyone" must know? << From what I can tell, we (the ones saying "huh?") are in the majority. There's a new article out in Genetic Engineering News. Blume's coauthor is John Prendergast. Go to 10-K Wizard and poke around. IMO (please, it's mine, everyone get their own!), the DGI website has been spruced up for a reason. Regarding my "huh?" status, here's how I value the two components...... NBSC, $90M with potential for rapid growth DGI, $40M At 80% of DGI, that comes out to $20/share. Thus my "huh?" Remember, Roach Motel!

To: Bob L who wrote (51)	6/28/2000 11:47:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 724

Want to make one other thing clear -- my valuation of DGI is based on the issued patent and the expansion of the Novo deal. If they can do and have done what they describe here....... dgibt.com and if the quality of their work resembles that of the SAB, then I would place a higher value on DGI. This is my concept (please, everyone get their own!) of how to invest in biotech...... find leveraged (and, if possible, also under-valued) opportunities, and invest early. Work hard to find out that the company stinks before the next guy can do such, and, if it doesn't stink, stick. It works. Other schemes also work well (see V1/Suzman/Silverman in 1998, for example). But this mechanism has worked, exceptionally, for over five years. It's largely documented here at SI. That's why I barf whenever I see one of these "how to invest in biotech" gurus, with "only buy companies with profits and late-stage projects" in their list of criteria. Ick. I feel tainted, just from typing it.